Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA: A German Multicenter Study

Abstract

Prospective results have demonstrated favorable safety and efficacy of [¹⁷⁷Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [¹⁷⁷Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles. <b>Methods:</b> In total, 111 patients were included in this multicenter retrospective analysis. Based on individual decisions, patients underwent uninterrupted continuation of therapy (continuous treatment) or reexposure after a therapy break (rechallenge treatment) between 2014 and 2023. Overall survival, 50% prostate-specific antigen (PSA) decline (measured 8–12 wk after treatment initiation or rechallenge), PSMA PET response, and grades per Common Terminology Criteria for Adverse Events were assessed. χ² tests, multivariable Cox regression analysis, and log-rank tests were applied for statistical analyses. <b>Results:</b> Patients received extended treatment with [¹⁷⁷Lu]Lu-PSMA, either as a continuous treatment (43/111, 38.7%) or as a rechallenge (68/111, 61.3%) treatment, with median cumulative doses of 57.4 or 60.8 GBq, respectively. Overall survival from the initiation of [¹⁷⁷Lu]Lu-PSMA was 31.3, 23.2, and 40.2 mo for the entire cohort, the continuous treatment group, and the rechallenge treatment group, respectively. The initial 50% PSA decline was significantly higher in the retreated group than in the continuous group (57/63 [90.4%] vs. 26/42 [61.9%]; <i>P</i> = 0.006). A 50% PSA decline was observed in 23 of 62 patients (37.1%) after the first rechallenge. The rate of grades 3–4 toxicity was comparable between continuous and rechallenge treatments (anemia, 7/43 [16.3%] vs. 13/68 [19.1%)], <i>P</i> = 0.6; leukocytopenia, 1/43 [2.3%] vs. 2/67 [3.0%], <i>P</i> = 0.3; thrombocytopenia, 3/43 [7.0%] vs. 3/68 [4.4%], <i>P</i> = 0.3; renal, 2/43 [4.7%] vs. 5/68 [7.4%], <i>P</i> = 0.2). <b>Conclusion:</b> Extended therapy with [¹⁷⁷Lu]Lu-PSMA is safe and has not been associated with increased grades 3–4 toxicity. Patient candidates for extended treatment experienced a favorable median survival of 31.3 mo from the first administration. Response under [¹⁷⁷Lu]Lu-PSMA rechallenge demonstrated preserved efficacy of [¹⁷⁷Lu]Lu-PSMA after a treatment break.